Clinical study of Shenqi Bufei Decoction combined with Montelukast sodium tablets in treating post-operative chronic cough in patients with non-small cell lung cancer
Objective To explore the clinical efficacy of Shenqi Bufei Decoction combined with Montelukast sodium tab-lets in treating post-operative chronic cough in patients with non-small cell lung cancer(NSCLC).Methods A total of 100 NSCLC patients with post-operative chronic cough were randomized 1∶1 to receive Montelukast sodium tablets(the control group)or Shenqi Bufei Decoction plus Montelukast sodium tablets(the treatment group).A 4-week treatment was performed in the both groups,aiming to compare cough symptoms,Leicester Cough Questionnaire in Mandarin-Chinese(LCQ-MC)score,lung function index(forced vital capacity[FVC],forced expiratory volume in the first second[FEV1],FEV1/FVC,peak ex-piratory flow[PEF]),inflammatory markers(interleukin-8[IL-8],tumor necrosis factor-α[TNF-α],procalcitonin[PCT],interleukin-6[IL-6]),traditional Chinese medicine(TCM)syndrome score,and the incidence of adverse reac-tions,recurrence rate and efficacy of the two groups were statistically analyzed.Results The total effective rate of the treatment group was better than that of the control group(98.00%[49/50]vs 82.00%[41/50],P<0.05).After treatment,the day-time and nighttime cough symptom scores in the both groups were significantly lower than those before treatment(P<0.05),but the LCQ-MC scores in the both groups were significantly increased(P<0.05),and the improvements were more common in the treatment group relative to the control group(both P<0.05).Af-ter treatment,the levels of FVC,FEV1,FEV1/FVC,and PEF in the both groups were significantly higher than those before treat-ment(P<0.05),and the increases were significantly higher in the treatment group compared to the control group(P<0.05).After treatment,the levels of IL-8,TNF-α,PCT,and IL-6 in the both groups were significantly lower than those before treatment(P<0.05),and which were significantly lower in the treatment group than in the control group(P<0.05).After treatment,the TCM syndrome scores of the both groups were significantly lower than those before treatment(P<0.05),which in the treatment group were significantly lower than those of the control group(P<0.05).The incidence of adverse reactions(4.00%[2/50]vs 18.00%[9/50])and the recurrence rate(4.08%[2/49]vs 24.39%[10/41])in the treatment group were significantly lower than those of the control group(both P<0.05).Conclusion Shenqi Bufei Decoction combined with Menelukast sodium tablet has a significant effect in NSCLC patients with post-operative chronic cough.It can effectively relieve cough symptoms,improve patients'pulmonary function,and improve the LCQ-MC score,decrease the incidence of adverse re-actions and recurrence rate.It has clinical application value.
Lung cancer,Non-small cell typePostoperativeChronic coughIntegrative traditional Chinese and Western medicine therapy
NETL
NSTL
万方数据
